$378 Million is the total value of Paradigm Biocapital Advisors LP's 25 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INCY | New | INCYTE CORP | $18,618,000 | – | 234,419 | +100.0% | 4.92% | – |
| HZNP | New | HORIZON THERAPEUTICS PUB L | $14,334,000 | – | 136,243 | +100.0% | 3.79% | – |
| UTHR | New | UNITED THERAPEUTICS CORP DEL | $13,570,000 | – | 75,635 | +100.0% | 3.59% | – |
| PRTA | New | PROTHENA CORP PLC | $9,799,000 | – | 267,946 | +100.0% | 2.59% | – |
| MRUS | New | MERUS N V | $6,603,000 | – | 249,738 | +100.0% | 1.75% | – |
| FULC | New | FULCRUM THERAPEUTICS INC | $5,037,000 | – | 212,961 | +100.0% | 1.33% | – |
| ALPN | New | ALPINE IMMUNE SCIENCES INC | $3,016,000 | – | 336,229 | +100.0% | 0.80% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LEGEND BIOTECH CORP | 8 | Q3 2023 | 10.7% |
| MIRATI THERAPEUTICS INC | 8 | Q3 2023 | 10.9% |
| VIRIDIAN THERAPEUTICS INC | 8 | Q3 2023 | 6.8% |
| IMMUNOCORE HLDGS PLC | 8 | Q3 2023 | 5.9% |
| SYNDAX PHARMACEUTICALS INC | 8 | Q3 2023 | 5.8% |
| VOR BIOPHARMA INC | 8 | Q3 2023 | 5.0% |
| INCYTE CORP | 7 | Q3 2023 | 8.6% |
| ARGENX SE | 7 | Q3 2023 | 8.7% |
| UNITED THERAPEUTICS CORP DEL | 7 | Q3 2023 | 7.7% |
| ALPINE IMMUNE SCIENCES INC | 7 | Q3 2023 | 2.1% |
View Paradigm Biocapital Advisors LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-02 |
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Paradigm Biocapital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.